Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Janus Henderson Group PLC cut its holdings in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 99.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,791 shares of the company's stock after selling 10,505,737 shares during the quarter. Janus Henderson Group PLC's holdings in Applied Therapeutics were worth $31,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC boosted its stake in shares of Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock valued at $35,000 after purchasing an additional 25,601 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Applied Therapeutics during the fourth quarter valued at about $35,000. Swiss National Bank acquired a new stake in shares of Applied Therapeutics during the fourth quarter valued at about $126,000. Intech Investment Management LLC boosted its stake in shares of Applied Therapeutics by 176.1% during the fourth quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock valued at $45,000 after purchasing an additional 33,567 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Applied Therapeutics during the fourth quarter valued at about $208,000. 98.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on APLT. Wall Street Zen raised Applied Therapeutics to a "sell" rating in a research note on Thursday, May 22nd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $1.50 target price on shares of Applied Therapeutics in a report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $6.10.

Applied Therapeutics Price Performance

Shares of NASDAQ:APLT traded down $0.00 during trading on Thursday, reaching $0.37. 828,627 shares of the stock were exchanged, compared to its average volume of 3,347,886. Applied Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $10.62. The stock has a fifty day moving average of $0.41 and a two-hundred day moving average of $1.46. The firm has a market cap of $52.81 million, a price-to-earnings ratio of -0.23 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.61 million. Sell-side analysts forecast that Applied Therapeutics, Inc. will post -0.65 EPS for the current year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.